Jobson V W, Nordqvist S R, Averette H E
Gynecol Oncol. 1983 Apr;15(2):154-9. doi: 10.1016/0090-8258(83)90069-0.
Twenty-six patients with advanced or recurrent epithelial ovarian carcinoma, FIGO Stages III and IV, were treated with combination chemotherapy using cyclophosphamide, doxorubicin, and cytosine arabinoside (CARA). In 17 cases, CARA was initiated following failure to single-agent chemotherapy, in all cases, melphalan. Nine patients with advanced cancer received CARA as their primary chemotherapy after maximum cytoreductive surgery. The overall response rate was 27%; however, in patients without prior chemotherapy the response rate was 44%. There were 6 complete responders, 1 partial responder, 13 patients with stable disease, and 6 who failed to respond to therapy. Four of six complete responders had remission durations greater than 10 months. The median progression free interval (PFI) of patients with residual tumor diameters less than 2 cm was significantly longer (P less than or equal to 0.04) than the PFI of patients with greater initial tumor burden. The median PFI of complete responders was significantly longer (P = 0.007) than PFI of patients with less than complete response. Previously untreated patients had longer median PFI than those who had failed previous chemotherapy (P = 0.07). The major dose-limiting toxicity of CARA was thrombocytopenia. Other myelosuppression was moderate and no cardiotoxicity was encountered.
26例晚期或复发性上皮性卵巢癌患者（国际妇产科联盟（FIGO）分期为III期和IV期）接受了环磷酰胺、阿霉素和阿糖胞苷（CARA）联合化疗。17例患者在单药化疗（所有病例均为美法仑）失败后开始使用CARA。9例晚期癌症患者在进行最大程度的肿瘤细胞减灭术后接受CARA作为初始化疗。总体缓解率为27%；然而，未接受过化疗的患者缓解率为44%。有6例完全缓解者、1例部分缓解者、13例病情稳定患者以及6例治疗无效患者。6例完全缓解者中有4例缓解持续时间超过10个月。残留肿瘤直径小于2 cm患者的无进展生存期（PFI）中位数显著长于初始肿瘤负荷较大患者的PFI中位数（P≤0.04）。完全缓解者的PFI中位数显著长于未完全缓解患者的PFI中位数（P = 0.007）。未接受过治疗的患者PFI中位数长于之前化疗失败的患者（P = 0.07）。CARA的主要剂量限制性毒性为血小板减少。其他骨髓抑制为中度，未出现心脏毒性。
